Precigen reported second quarter 2026 financial results and provided business updates on Tuesday, August 4, 2026.

Helen Sabzevari, PhD, President and CEO, participated in a fireside chat

The event will be hosted by Brian Cheng, Senior Biotech Analyst at J.P. Morgan. Precigen participants will include Helen Sabzevari, PhD, President and CEO, and Phil Tennant, Chief Commercial Officer. This event is available to J.P. Morgan clients.

Precigen reported first quarter 2026 financial results and provided business updates on Wednesday, May 13, 2026.

Helen Sabzevari, PhD, President and CEO, and Phil Tennant, Chief Commercial Officer, of Precigen, participated in a virtual fireside chat with H.C. Wainwright.

Precigen reported full year 2025 financial results and provided business updates on Wednesday, March 25, 2026.

Fireside Chat at the Biotech Showcase 2026 
Panelist: Helen Sabzevari, PhD, President and CEO
Monday, January 12, 2026 at 10:30 AM PT
 

Company Presentation at the J.P. Morgan Healthcare Conference
Presenter: Helen Sabzevari, PhD, President and CEO
Thursday, January 15, 2026 at 7:30 AM PT
View webcast

Precigen reported third quarter 2025 financial results and provide business updates.

Precigen hosted a lunch and learn product theater titled, "A New FDA-approved Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis in Adults". Precigen also had a booth at the conference where visitors met team members and learned more about the company.

Helen Sabzevari, PhD, Precigen's President and CEO, presented the keynote titled, "Drug Development Reinvented: Precision Strategies to Rapidly Deliver Transformative Therapies for Patients" on Thursday, September 18 at 3:05 PM ET at the Cell & Gene Therapy International conference during Biotech Week Boston.

Precigen discussed the recent approval of the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis (RRP).

Moderator: Swayampakula Ramakanth, PhD, Managing Director, Equity Research, H.C. Wainwright
Participants: Helen Sabzevari, PhD, President and CEO, Precigen and Phil Tennant, Chief Commercial Officer, Precigen

Precigen discussed the recent approval of the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis (RRP).

Host: Jennifer Kim, Biotech Analyst, Cantor Participants: Helen Sabzevari, PhD, President and CEO, Precigen and Phil Tennant, Chief Commercial Officer, Precigen

Note: This event is for institutional clients of Cantor only - Please contact your Cantor Sales representative if interested in participating.

Precigen conference call provided additional details regarding the FDA approval of PAPZIMEOS (zopapogene imadenovec-drba), including key aspects of the label and commercialization.